Licoricidin (LCD) (intraperitoneal injection; 5, 10, or 20 mg/kg; once daily; 15 days) significantly inhibited the growth of SW480 xenografts in nude mice with an inhibitory rate of 43.5%. Licoricidin ( LCD) (intraperitoneal injection; 5, 10, or 20 mg/kg; once daily; 32 days) reduces pulmonary metastasis and the expression of CD45, CD31, HIF-1α, iNOS, COX-2, and VEGF-A in tumor tissues , additionally, decreased protein expression of VEGF-R2, VEGF-C, VEGF-R3, and LYVE-1 in tumor tissues of licoricidin-treated mice.
| Animal Model: | SW480 xenografted tumor growth in nude mice |
| Dosage: | 5, 10, or 20 mg/kg |
| Administration: | Intraperitoneal injection; once daily; 15 days |
| Result: | Decreased tumor volumes. |
| Animal Model: | BALB/c mouse orthotopic model |
| Dosage: | 5, 10, or 20 mg/kg |
| Administration: | Intraperitoneal injection; 5, 10, or 20 mg/kg; once daily; 32 days |
| Result: | Inhibited Lung Metastasis of 4T1 Murine Mammary Carcinoma cells. |
